@article{ceb3f6584d0449d19361d41c634bdbf9,
title = "Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983",
abstract = "To compare the efficacy of four cycles of paclitaxel-bleomycin, etoposide, and cisplatin (T-BEP) to four cycles of bleomycin, etoposide, and cisplatin (BEP) in previously untreated patients with intermediate-prognosis germ-cell cancer (GCC).",
keywords = "Adolescent, Adult, Antibiotics, Antineoplastic, Antineoplastic Agents, Antineoplastic Agents, Phytogenic, Antineoplastic Combined Chemotherapy Protocols, Bleomycin, Cisplatin, Disease-Free Survival, Etoposide, Granulocyte Colony-Stimulating Factor, Humans, Male, Middle Aged, Neoplasms, Germ Cell and Embryonal, Paclitaxel, Treatment Outcome",
author = "{de Wit}, Ronald and Iwona Skoneczna and Gedske Daugaard and {De Santis}, Maria and August Garin and Nina Aass and Witjes, {Alfred J} and Albers, {Peter Hjorth} and White, {Jeffery D} and Germa-Lluch, {Jos{\'e} R} and Sandrine Marreaud and Laurence Collette",
year = "2012",
doi = "10.1200/JCO.2011.37.0171",
language = "English",
volume = "30",
pages = "792--9",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "Lippincott Williams and Wilkins",
number = "8",
}